Common

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
Monday, April 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Investview, Inc. (“INVU”) Reports Full Year 2023 Financial Results, Operational Highlights and a Year-End Message from the CEO

Retrieved on: 
Monday, April 1, 2024
Geothermal energy, Growth, Environment, Fintech, Common, Research, Acquisition, Water, Depreciation, Miner, OTCQB, Net income, Marketing, Mining, Cryptocurrency

Haverford, PA, April 01, 2024 (GLOBE NEWSWIRE) -- Investview, Inc. (OTCQB: INVU), a diversified financial technology (FinTech) company that provides financial education tools, content and research, through a global distribution network; digital asset products and services that support blockchain technologies and Bitcoin mining operations; and, which is developing a retail brokerage and financial markets business that plans to offer investors an online trading platform focused on enabling self-directed retail brokerage services, is pleased to announce its financial results for the twelve months ended December 31, 2023.

Key Points: 
  • Net Revenue increased 9.8% to $67.9 million for the twelve months ended December 31, 2023, as compared to $61.8 million for the comparable prior year period.
  • Total stockholders’ equity at December 31, 2023 was $18.8 million, an increase of $1.4 million or 8.1% from the $17.4 of stockholders’ equity at December 31, 2022.
  • I am pleased to announce the 2023 financial results and operational highlights for Investview.
  • With approximately $20.9 million in cash and equivalents, we have an advantageous path forward to achieving our growth plans.

Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement

Retrieved on: 
Monday, April 1, 2024
Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Share (finance), Form S-3, Prospectus, P.C, Security (finance)

The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.

Key Points: 
  • The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.
  • In a concurrent private placement, the Company also issued common warrants (“Common Warrants”) to the same investors.
  • Aggregate gross proceeds to the Company from both transactions were approximately $2.76 million.
  • The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No.

Watsco Boosts Annual Dividend 10% to $10.80 Per Share

Retrieved on: 
Monday, April 1, 2024
WSO, Common, Holding company

MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $2.70 on each outstanding share of its Common and Class B common stock payable on April 30, 2024 to shareholders of record at the close of business on April 15, 2024.

Key Points: 
  • MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- Watsco, Inc.’s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $2.70 on each outstanding share of its Common and Class B common stock payable on April 30, 2024 to shareholders of record at the close of business on April 15, 2024.
  • Albert H. Nahmad, Watsco’s Chairman & CEO, stated: “We are pleased to increase dividends to shareholders, reflecting our confidence in the prospects of our business, which is fundamentally supported by our strong balance sheet.”
    Watsco has paid dividends to shareholders for 50 consecutive years.
  • The Company’s philosophy is to share cash flow through dividends while maintaining a conservative balance sheet with continued capacity to build its distribution network.
  • Future changes in dividends are considered in light of investment opportunities, cash flow, general economic conditions and Watsco’s overall financial condition.

AEON Biopharma Announces Redemption of Public Warrants

Retrieved on: 
Sunday, March 31, 2024
AEON, Transfer, Common stock, Warrant, Exercise, Common, Sale, Attention, IPO, Fair market value, Redemption, Security (finance)

At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.

Key Points: 
  • At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.
  • Any Public Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be delisted, void and no longer exercisable, and the holders will have no rights with respect to those Public Warrants, except to receive the Redemption Price (or as otherwise described in the redemption notice for holders who hold their Public Warrants in “street name”).
  • The Redemption Fair Market Value means the volume weighted average price of the Common Stock for the ten trading days immediately following the date of the notice of redemption.
  • Questions concerning redemption and exercise of the Public Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

AERWINS Technologies Announces 1-For-100 Reverse Stock Split

Retrieved on: 
Thursday, March 28, 2024
Common stock, Exercise, Common, Security (finance)

LOS ANGELES, CA, March 28, 2024 (GLOBE NEWSWIRE) -- AERWINS Technologies Inc. (Nasdaq: AWIN) (“AERWINS” or “the Company”) today announced that the Company’s board of directors has resolved to effectuate a reverse stock split of AERWINS’s issued and outstanding common stock, par value $0.000001 per share (“Common Stock”) and has determined the ratio to be 1-for-100.

Key Points: 
  • LOS ANGELES, CA, March 28, 2024 (GLOBE NEWSWIRE) -- AERWINS Technologies Inc. (Nasdaq: AWIN) (“AERWINS” or “the Company”) today announced that the Company’s board of directors has resolved to effectuate a reverse stock split of AERWINS’s issued and outstanding common stock, par value $0.000001 per share (“Common Stock”) and has determined the ratio to be 1-for-100.
  • AERWINS’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company’s Annual Meeting of Stockholders held on November 20, 2023.
  • The reverse stock split will become effective at the market open on April 2, 2024, (“Effective Time”) and the Company’s Common Stock is expected to begin trading on a reverse stock split-adjusted basis on the Nasdaq Capital Market (“Nasdaq”) as of the open of trading on April 2, 2024, under the existing ticker symbol, “AWIN.” The reverse stock split is intended to increase the price per share of the Company’s Common Stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).
  • Registered stockholders holding pre-reverse stock split shares of Common Stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares.

New Zealand Mānuka Honey: Science Confirms Genetic Uniqueness And Urges Informed Choices For Consumers

Retrieved on: 
Thursday, March 28, 2024
Honey, Skin care, Unique, UMF, Research, DNA, News, Common, Plant & Food Research, Plant, Immune system, AgResearch, Tree, Leptospermum

This news empowers consumers to make informed choices when seeking genuine mānuka honey with its renowned antibacterial, anti-inflammatory, and antioxidant properties.

Key Points: 
  • This news empowers consumers to make informed choices when seeking genuine mānuka honey with its renowned antibacterial, anti-inflammatory, and antioxidant properties.
  • The Unique Mānuka Factor Honey Association (UMFHA), the trusted leader in mānuka honey quality and authentication, applauds the clarity for consumers of these latest findings.
  • The findings confirmed that mānuka trees from New Zealand and Tasmania (Australia) are genetically distinct enough to be considered separate species.
  • "Consumers choosing mānuka honey for its health benefits need accurate information to select the ideal product," says Tony Wright, CEO of the UMFHA.

Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Retrieved on: 
Wednesday, March 27, 2024
Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Prospectus, Form S-3, P.C, Security (finance)

In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”).

Key Points: 
  • In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”).
  • Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement.
  • The Common Warrants are exercisable immediately subject to registration and expire 5 years after the initial issuance date.
  • The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No.

ProStar Holdings Announces Closing of First Tranche of Private Placement for Gross Proceeds of US$1 Million

Retrieved on: 
Wednesday, March 27, 2024
Indian stock exchange, Interest, Exercise, Minority, Common, The Company, Warrant, Sale, Regulation, Acquisition, News, Disclosure, National instrument, Marketing, Intervention (law), Multilateral, Related, Person, Security (finance)

The Company will use the proceeds from the First Tranche for sales, marketing, and working capital requirements.

Key Points: 
  • The Company will use the proceeds from the First Tranche for sales, marketing, and working capital requirements.
  • Wayne Moore, a director of the Company (the “Interested Party”), purchased or acquired direction or control over a total of 6,250,000 Units as part of the First Tranche.
  • The placement to the Interested Party constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”).
  • Wayne Moore, a director of the Company, acquired 6,250,000 Units at the Offering Price for aggregate consideration of US$750,000.